Andrzej Jakubowiak to T-Lymphocytes
This is a "connection" page, showing publications Andrzej Jakubowiak has written about T-Lymphocytes.
Connection Strength
0.239
-
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study. Cancer Immunol Res. 2026 Apr 02; 14(4):528-542.
Score: 0.144
-
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma. Sci Transl Med. 2026 May 27; 18(851):eadx1799.
Score: 0.036
-
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576.
Score: 0.030
-
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6).
Score: 0.028